Moclobemide is a short-acting, reversible inhibitor of monoamine oxidase (MAO). It is a benzamide derivative which inhibits the deamination of serotonin, norepinephrine and dopamine. This action leads to increased concentrations of these neurotransmitters, which may account for the antidepressant activity of moclobemide. Moclobemide is the first of a new class of antidepressants known as reversible inhibitors of monoamine oxidase type A (RIMA). MAOs are currently subclassified into 2 types, A and B, which differ in their substrate specificity. Moclobemide preferentially inhibits MAO-A; at a 300 mg dose, the inhibition of MAO-A is approximately 80%, while that of MAO-B is approximately 20 to 30%. The estimated MAO-A inhibition is short-lasting (maximum 24 hours) and reversible.
Moclobemide is a benzamide derivative which is a reversible inhibitor of monoamine oxidase type A. It inhibits the deamination of seratonin, dopamine and noradrenaline which leads to increased extracellular concentrations of these neuronal transmitters which may account for its antidepressant activity. Moclobemide relieves symptoms such as dysphoria, lack of drive, inability to concentrate and exhaustion. These effects most often appear within the first week of therapy. Moclobemide also relieves symptoms related to social phobia.
Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied in anxiety disorders. Nearly all meta-analyses and most comparative studies indicated that in the acute management of depression this drug is more efficacious than placebo and as efficacious as tricyclic (or some heterocyclic) antidepressants or selective serotonin reuptake inhibitors (SSRIs). There is a growing evidence that moclobemide is not inferior to other antidepressants in the treatment of subtypes of depression, such as dysthymia, endogenous (unipolar and bipolar), reactive, atypical, agitated, and retarded depression as with other antidepressants limited evidence suggests that moclobemide has consistent long-term efficacy.
When depression occurs, there may be a decrease in the amount of chemicals released from nerve cells in the brain. These chemicals are called monoamines. Monoamines may be broken down by a chemical called monoamine oxidase type A. Moclobemide reversibly prevents monoamine oxidase A from breaking down the monoamines. This results in an increased amount of active monoamines in the brain. By increasing the amount of monoamines in the brain, the imbalance of chemicals thought to cause depression is altered. This helps relieve depression. Moclobemide may also be used in the treatment of social phobia. It is not fully understood how it works in this illness.